1-7 of 7
Steve Weitman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors

Alain C. Mita, Lisa A. Hammond, Peter L. Bonate, Geoffrey Weiss, Heather McCreery, Samira Syed, Mitchell Garrison, Quincy S.C. Chu, Johann S. DeBono, Christopher B. Jones, Steve Weitman, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (17): 5207–5215.
https://doi.org/10.1158/1078-0432.CCR-06-0179
Published: 01 September 2006
View article titled, Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors
Open the PDF for Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors in another window
Journal Articles

A Phase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid Tumors

Scot Ebbinghaus, Eric Rubin, Evan Hersh, Lee D. Cranmer, Peter L. Bonate, Robert J. Fram, Antti Jekunen, Steve Weitman, Lisa A. Hammond
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7807–7816.
https://doi.org/10.1158/1078-0432.CCR-05-0909
Published: 08 November 2005
View article titled, A Phase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors

Casey Cunningham, Leonard J. Appleman, Miora Kirvan-Visovatti, David P. Ryan, Eileen Regan, Svetislava Vukelja, Peter L. Bonate, Francis Ruvuna, Robert J. Fram, Antti Jekunen, Steve Weitman, Lisa A. Hammond, Joseph P. Eder, Jr.
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7825–7833.
https://doi.org/10.1158/1078-0432.CCR-05-0058
Published: 08 November 2005
View article titled, Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors
Open the PDF for Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors in another window
Journal Articles

Enhancement of DNA Ligase I Level by Gemcitabine in Human Cancer Cells

Daekyu Sun, Rheanna Urrabaz, Susan Kelly, Myhanh Nguyen, Steve Weitman
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (4): 1189–1195.
Published: 01 April 2002
View article titled, Enhancement of DNA Ligase I Level by Gemcitabine in Human Cancer Cells
Open the PDF for Enhancement of DNA Ligase I Level by Gemcitabine in Human Cancer Cells in another window
Journal Articles

Elevated Expression of DNA Ligase I in Human Cancers

Daekyu Sun, Rheanna Urrabaz, Myhanh Nguyen, Jennifer Marty, Stephanie Stringer, Edna Cruz, Leticia Medina-Gundrum, Steve Weitman
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (12): 4143–4148.
Published: 01 December 2001
View article titled, Elevated Expression of DNA Ligase I in Human Cancers
Open the PDF for Elevated Expression of DNA Ligase I in Human Cancers in another window
Journal Articles

A Phase I Study of Irinotecan in Pediatric Patients: A Pediatric Oncology Group Study

Susan Blaney, Stacey L. Berg, Charles Pratt, Steve Weitman, Jim Sullivan, Lori Luchtman-Jones, Mark Bernstein
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (1): 32–37.
Published: 01 January 2001
View article titled, A Phase I Study of Irinotecan in Pediatric Patients: A Pediatric Oncology Group Study
Open the PDF for A Phase I Study of Irinotecan in Pediatric Patients: A Pediatric Oncology Group Study in another window
Journal Articles

The New Dioxolane, (-)-2′-Deoxy-3′-oxacytidine (BCH-4556, Troxacitabine), Has Activity against Pancreatic Human Tumor Xenografts

Steve Weitman, Jennifer Marty, Jacques Jolivet, Celine Locas, Daniel D. Von Hoff
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (4): 1574–1578.
Published: 01 April 2000
View article titled, The New Dioxolane, (-)-2′-Deoxy-3′-oxacytidine (BCH-4556, Troxacitabine), Has Activity against Pancreatic Human Tumor Xenografts
Open the PDF for The New Dioxolane, (-)-2′-Deoxy-3′-oxacytidine (BCH-4556, Troxacitabine), Has Activity against Pancreatic Human Tumor Xenografts in another window